Nigatu Abebe from Ethiopia sits on a bed in the Leishmaniasis Research and Treatment Centre (LRTC) at the University of Gondar in Ethiopia. He looks very frail and has been battling against visceral leishmaniasis (VL), also known as kala-azar, and HIV for 11 years.
2018 showed us that another way to develop life-saving drugs is possible. Travel the globe with us to see how 15 years of patient-focused research and development (R&D) are bearing fruit for the most neglected patients.
More than 180 friends, supporters, partners, celebrities, and global health influencers celebrated our 15-year anniversary with us at our Making Medical History Gala in New York City.
Meeting opened by Ugandan Prime Minister convenes public & private sector partners from more than 40 countries
On 4 October 2018, DNDi held its 11th Partners’ Meeting in Kampala, Uganda. The meeting gathered together more than 400 partners and stakeholders from over 150 institutions and more than 40 countries, primarily African.
DNDi is very pleased to announce the appointment of Joelle Tanguy as Director of External Affairs and a member of the organization’s Executive Team.
In early October, 18 journalists from 11 African countries converged in Kampala, Uganda for DNDi’s first-ever training on health and science journalism. The three-day training was conducted during a week of workshops and meetings related to the work of DNDi and its many partners, culminating in the 11th DNDi Partners’ Meeting on 4 October 2018.
New agreement between Clinical Research Malaysia & FIND on R&D for hepatitis C diagnostic tests continues an existing Malaysian partnership with DNDi for hepatitis C treatment
The Foundation for Innovative New Diagnostics (FIND) and Clinical Research Malaysia (CRM), both DNDi partners, recently signed a memorandum of understanding (MoU) to collaborate in the research and development of an innovative hepatitis C diagnostic testing strategy.
Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme
DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.
DNDi and GARDP have issued a call for nominations for a new Board member who would also serve as Treasurer of the Board.
Can post-kala-azar dermal leishmaniasis threaten progress against kala-azar?
लौटकर पलटवार करती बीमारीक्या लेशमेनियासिस का एक प्रकार भारत मे उन्मूलन प्रयासों के लिए चुनौती बन सकता है? रूबी देवी ने जब भारत के सबसे गरीब राज्य बिहार से देश की राजधानी का रूख किया तो उन्हें लगा कि विसरल लेशमेनियासिस के साथ चल रही उनकी आज़माइश अब पूरी हुई | विसरल लेशमेनियासिस जिसे भारत […]
Hidden in the mountains, forests, and pastures of the central Andean region in Colombia are small, remote communities where Chagas disease still takes a heavy toll.
Yerko grew up in Bolivia in the small community of El Forestal in the east of the country. As a child, he and his family lived in a house with walls made of adobe bricks and a roof of palm leaves. Hidden inside the cracks and crevices in the walls and roof were kissing bugs. Yerko wanted to become a pharmacist to help people in need, but became a victim of Chagas disease.
“It just went completely white.” This is the how fisherman Akoyo Osumaka describes going blind in 2011, in the remote village of Babagulu in the Democratic Republic of Congo (DRC). It was a slow, creeping blindness that began a year earlier. It robbed him of his livelihood and threw his family life into disarray.
The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.
Daiichi Sankyo RD Novare and DNDi are pleased to announce the financial support of the Japan Global Health Innovative Technology Fund to their new collaboration on natural products.
Phase II/III study results confirmed that fexinidazole, DNDi’s first new chemical entity is safe and effective, and presents significant advantages over current treatment as it removes the need for lumbar puncture and systematic patient hospitalization. A regulatory dossier has been submitted to the European Medicines Agency for fexinidazole as the first all-oral treatment for sleeping sickness.
Three new chemical entities entered the pre-clinical pipeline, bringing to six the number of new compounds progressing in the leishmaniasis portfolio, with two already nominated as clinical candidates to progress to Phase I. The first patient was recruited in India in Phase II studies to test new treatments for PKDL, while clinical sites were being prepared in Bangladesh and Sudan. A site was initiated in Sudan for a Phase III study to test a new combination treatment for leishmaniasis in the African region. In Latin America, a Phase II study on new combination treatments for cutaneous leishmaniasis progressed well.
Two Phase II trials are ongoing, with the study in Bolivia on benznidazole for improved treatment of chronic indeterminate Chagas disease having completed recruitment at the end of 2017, and a study in Spain in the early stages of patient recruitment to evaluate fexinidazole as Chagas treatment. A pilot project to increase access to diagnosis and treatment in five endemic communities in Colombia showed excellent interim results and will report one-year results in mid-2018. In 2018, DNDi and Fundación Mundo Sano will launch a new Chagas Disease Regional Access Framework.
The portfolio of potential filaricidal treatments continues to progress, with emodepside (Bayer) and the antibiotic TylAMac (AbbVie) that have entered healthy volunteer Phase I studies with other pre-clinical candidates.